Vivo Capital, LLC - Q3 2023 holdings

$913 Million is the total value of Vivo Capital, LLC's 53 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 22.9% .

 Value Shares↓ Weighting
GTH  Genetron Holdings Ltdads$104,570,306
+1283.9%
8,124,1740.0%11.46%
+2094.6%
NewSoleno Therapeutics Inc$94,523,2743,203,093
+100.0%
10.36%
HRMY  Harmony Biosciences Holdings Inc$85,406,714
-6.9%
2,606,2470.0%9.36%
+47.8%
VRNA  Verona Pharma PLCads$69,273,663
-22.9%
4,249,9180.0%7.59%
+22.4%
AVDL BuyAvadel Pharmaceuticals PLCadr$42,193,208
-33.1%
4,096,428
+7.0%
4.62%
+6.1%
TARS  Tarsus Pharmaceuticals Inc$40,199,294
-1.7%
2,262,2000.0%4.40%
+56.1%
SVA  Sinovac Biotech Ltd.$38,173,000
-93.8%
5,900,0000.0%4.18%
-90.2%
GERN  Geron Corp$35,032,224
-34.0%
16,524,6340.0%3.84%
+4.8%
TERN  Terns Pharmaceuticals Inc$33,489,700
-42.5%
6,657,9920.0%3.67%
-8.8%
GRCL BuyGracell Biotechnologies Incsponsored ads$31,337,695
+107.2%
10,881,144
+174.1%
3.43%
+228.8%
VRDN  Viridian Therapeutics Inc$25,743,695
-35.5%
1,678,2070.0%2.82%
+2.3%
OLMA BuyOlema Pharmaceuticals Inc$23,140,244
+91.3%
1,873,704
+39.9%
2.54%
+203.6%
COGT  Cogent Biosciences Inc$21,888,175
-17.7%
2,244,9410.0%2.40%
+30.7%
ALXO  ALX Oncology Holdings Inc$20,256,230
-36.1%
4,220,0480.0%2.22%
+1.4%
BuyArcellx Inc.$18,067,912
+31.7%
503,565
+16.1%
1.98%
+109.0%
 Ventyx Biosciences Inc$14,658,665
+5.9%
422,0750.0%1.61%
+68.0%
NewRayzebio Inc$14,065,387633,576
+100.0%
1.54%
 Icosavax, Inc.$13,210,402
-22.0%
1,704,5680.0%1.45%
+23.9%
 Astria Therapeutics Inc$12,541,745
-10.4%
1,681,1990.0%1.37%
+42.1%
 Verastem Inc$12,507,688
+9.3%
1,538,4610.0%1.37%
+73.4%
CMPS NewCompass Pathway PLCsponsored ads$11,899,2001,608,000
+100.0%
1.30%
ZLAB BuyZai Lab Ltd ADRadr$11,051,472
-10.5%
454,606
+2.0%
1.21%
+42.0%
ALPN  Alpine Immune Sciences Inc$10,475,754
+11.4%
914,9130.0%1.15%
+76.9%
CRNX NewCrinetics Pharmaceuticals Inc$10,409,000350,000
+100.0%
1.14%
DYN BuyDyne Therapeutics Inc$9,274,819
+42.7%
1,035,136
+79.2%
1.02%
+126.3%
BuyIO Biotech Inc$8,704,549
+47.7%
6,173,439
+104.7%
0.95%
+134.4%
NewApogee Therapeutics Inc$8,520,000400,000
+100.0%
0.93%
KALV  KalVista Pharmaceuticals Inc.$8,243,357
+7.0%
856,0080.0%0.90%
+69.7%
DCTH BuyDelcath Systems, Inc.$7,513,524
+9.3%
1,855,191
+57.4%
0.82%
+73.6%
SVRA NewSavara Inc$7,232,4591,913,349
+100.0%
0.79%
CMPX  Compass Therapeutics Inc$7,005,365
-38.1%
3,556,0230.0%0.77%
-1.8%
ALLK  Allakos Inc$6,782,760
-47.9%
2,988,0000.0%0.74%
-17.4%
 Aadi Bioscience Inc$6,456,2770.0%509,5720.0%0.71%
+58.5%
ACRS  Aclaris Therapeutics, Inc.$6,155,622
-33.9%
898,6310.0%0.67%
+4.8%
TIL  Instil Bio Inc$5,344,345
-22.3%
12,486,7870.0%0.59%
+23.4%
ORIC NewOric Pharmaceuticals Inc$4,706,561777,944
+100.0%
0.52%
BOLT  Bolt Therapeutics Inc$4,026,143
-18.7%
3,871,2910.0%0.44%
+28.9%
ARWR  Arrowhead Pharmaceuticals Inc$3,692,234
-24.6%
137,4110.0%0.40%
+19.8%
DBVT  DBV Technologies SAsponsored adr$3,684,070
-28.4%
2,708,8750.0%0.40%
+13.8%
 Sera Prognostics Inc$3,452,180
-43.6%
1,856,0110.0%0.38%
-10.4%
IOVA  Iovance Biotherapeutics Inc$2,980,509
-35.4%
655,0570.0%0.33%
+2.8%
NewUnicycive Therapeutics$2,984,3313,470,152
+100.0%
0.33%
ALGS  Aligos Therapeutics Inc$2,649,631
-23.1%
3,547,0300.0%0.29%
+21.8%
FULC SellFulcrum Therapeutics Inc$2,308,800
+27.2%
520,000
-5.5%
0.25%
+102.4%
CLNN SellClene Inc$1,396,738
-62.3%
2,645,338
-41.5%
0.15%
-40.2%
IMPL  Impel NeuroPharma Inc$1,240,459
-66.1%
2,884,7890.0%0.14%
-46.2%
ASLN SellAslan Pharmaceuticals Ltdads$1,068,181
-89.7%
568,182
-80.0%
0.12%
-83.7%
BCAB SellBioAtla Inc$908,108
-52.5%
534,181
-16.2%
0.10%
-25.0%
CDXS  Codexis, Inc$733,592
-32.5%
388,1440.0%0.08%
+6.7%
RZLT SellRezolute Inc$639,459
-34.0%
484,439
-1.0%
0.07%
+4.5%
AMRS  Amyris, Inc$465,050
-94.2%
7,750,8280.0%0.05%
-90.7%
FIXX  Homology Medicines, Inc.$432,980
+32.2%
370,0680.0%0.05%
+104.3%
DTIL  Precision Biosciences Inc$47,869
-35.1%
140,2550.0%0.01%0.0%
IMUX ExitImmunic Inc$0-632,184
-100.0%
-0.11%
KDNY ExitChinook Therapeutics Inc$0-934,879
-100.0%
-2.48%
VECT ExitVectivBio Holding AG$0-2,333,300
-100.0%
-2.72%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-11-08
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ACLARIS THERAPEUTICS INC29Q3 202333.5%
CODEXIS INC29Q3 20238.0%
ASCENDIS PHARMA A/S25Q3 202224.0%
KALVISTA PHARMACEUTICALS INC25Q3 20233.9%
Verona Pharma PLC ADR24Q3 20237.6%
AMYRIS INC23Q3 20238.8%
EIGER BIOPHARMACEUTICALS INC23Q1 20228.7%
Zai Lab Ltd ADR22Q3 20231.8%
Arrowhead Pharmaceuticals Inc21Q3 20236.9%
HOMOLOGY MEDICINES INC21Q3 20233.7%

View Vivo Capital, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Vivo Capital, LLC Q3 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
SINOVAC BIOTECH LTDSold outAugust 27, 201800.0%

View Vivo Capital, LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-02-07
13F-HR2023-11-08
13F-HR2023-08-14
13F-HR2023-05-15
13F-HR2023-02-13
13F-HR2022-11-14
13F-HR2022-08-15
13F-HR2022-05-13
13F-HR2022-02-11
13F-HR2021-11-15

View Vivo Capital, LLC's complete filings history.

Compare quarters

Export Vivo Capital, LLC's holdings